FGF-2 Polyclonal Antibody
¥680.00
- 产品信息
商品描述
靶点-Target
Chromogranin A
反应性
Human,Mouse,Rat
应用
WB,IHC,IF,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Unmodified
MW(Observed)
68kD
推荐稀释比
WB 1:500-1:2000;IHC 1:100-1:300;ELISA 1:10000;IF 1:50-200
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
The antiserum was produced against synthesized peptide derived from human Chr-A. AA range:311-360
特异性
Chr-A Polyclonal Antibody detects endogenous levels of Chr-A protein.
基因名称
CHGA
蛋白名称
Chromogranin-A
别名
CHGA;Chromogranin-A;CgA;Pituitary secretory protein I;SP-I
Organism-1
Human
基因ID-1
1113
SwissProt-1
P10645
Organism-2
Mouse
基因ID-2
12652
SwissProt-2
P26339
Organism-3
Rat
SwissProt-3
P10354
背景
The protein encoded by this gene is a member of the chromogranin/secretogranin family of neuroendocrine secretory proteins. It is found in secretory vesicles of neurons and endocrine cells. This gene product is a precursor to three biologically active peptides; vasostatin, pancreastatin, and parastatin. These peptides act as autocrine or paracrine negative modulators of the neuroendocrine system. Two other peptides, catestatin and chromofungin, have antimicrobial activity and antifungal activity, respectively. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2014],
细胞定位
[Serpinin]: Secreted . Cytoplasmic vesicle, secretory vesicle . Pyroglutaminated serpinin localizes to secretory vesicle. .; Cytoplasmic vesicle, secretory vesicle . Cytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle . Secreted . Associated with the secretory granule membrane through direct interaction to SCG3 that in turn binds to cholesterol-enriched lipid rafts in intragranular conditions. In pituitary gonadotropes, located in large secretory granules. .
